Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cartalax vs KPV
An educational, source-based comparison of Cartalax and KPV — how each peptide works, what it's researched for, and what to know before going deeper.
Tripeptide bioregulator researched for cartilage and joint support.
A synthetic tripeptide (Ala-Glu-Asp) in the Khavinson short-peptide family. Research suggests gene-expression modulation in chondrocytes and fibroblasts, supporting extracellular matrix synthesis and reducing cartilage degradation markers.
- Osteoarthritis and cartilage repair
- Joint mobility in aging
- Tendon and ligament integrity
- • Preclinical and Russian clinical data only.
- • Not FDA-approved.
The C-terminal tripeptide (Lys-Pro-Val) of α-MSH. Research suggests anti-inflammatory effects via melanocortin pathways and intracellular NF-κB modulation — without the pigmentation effects of full-length α-MSH.
- Inflammatory bowel disease models
- Atopic dermatitis (topical research)
- Mast cell stabilization
- • Not FDA-approved.
- • Most evidence is preclinical.
Cartalax vs KPV — Key differences
- Class: Cartalax is classified as Musculoskeletal · Bioregulator, while KPV is Gastrointestinal · Anti-inflammatory.
- Primary research focus: Cartalax — osteoarthritis and cartilage repair; KPV — inflammatory bowel disease models.
- Tag: Joint · Bioregulator vs Gut · Anti-inflammatory.